Detalhe da pesquisa
1.
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
Haematologica
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634126
2.
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
Am J Hematol
; 99(5): 862-870, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38380817
3.
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.
Haematologica
; 108(2): 420-432, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35924583
4.
FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Biol Blood Marrow Transplant
; 26(11): 2165-2173, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32717436
5.
Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval.
Biol Blood Marrow Transplant
; 25(1): 183-190, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30153492
6.
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
Haematologica
; 108(1): 273-277, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36134457
7.
Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.
Front Cell Dev Biol
; 12: 1376554, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38694825
8.
Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Leukemia
; 38(4): 865-876, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388647
9.
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191.
Cancers (Basel)
; 16(5)2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38473239
10.
Severe granulocytic dysplasia with vacuolar rosettes in a myelodysplastic syndrome with low-copy KMT2A gain.
Br J Haematol
; 180(3): 320, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29048106
11.
Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia.
Cancers (Basel)
; 15(2)2023 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36672303
12.
Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.
Bone Marrow Transplant
; 58(4): 377-385, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36577856
13.
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.
Clin Cancer Res
; 29(20): 4057-4067, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37698881
14.
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Blood Adv
; 7(17): 4950-4961, 2023 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37339483
15.
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.
Blood Cancer J
; 13(1): 77, 2023 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37173322
16.
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
Cancers (Basel)
; 15(5)2023 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900400
17.
SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
Clin Lymphoma Myeloma Leuk
; 22(12): e1059-e1066, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117041
18.
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.
Cancers (Basel)
; 14(12)2022 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35740603
19.
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Bone Marrow Transplant
; 57(6): 934-941, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35393528
20.
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.
Cancers (Basel)
; 14(9)2022 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35565471